Objective study the clinical efficacy of high-dose interleukin-2( IL-2 ) immunotherapy after chemotherapy of malignant lymphoma. Methods review 40 malignant lymphoma patients treated with high-dose interleukin-2 after they had treated with chemotherapy and acquired remission, compared with 40 randomly selected malignant lymphoma patients without immunotherapy after they had treated with chemotherapy and acquired remission of Beijing Military General Hospital from January 2005 to May 2010. Detect T lymphocyte subsets in peripheral blood of both groups, and all patients were followed up. Results there was a significant increase in T lymphocyte subsets in peripheral blood of the therapy group. The recurrence rate at the end of follow up : therapy group 17. 5 ％ , control group 32. 5％ ; median survival time : therapy group 34. 5 ± 2. 0( 20 ～ 60 ) months , control group 23. 2 ±2. 0( 12 ～ 60 )months. Conclusion high-dose interleukin-2 therapy of malignant lymphoma patients after remission can be an effective therapy method to improve immune function.reduce recurrence rate , prolong survival time.%目的 探讨恶性淋巴瘤化疗缓解后行大剂量白介素-2 (IL-2)免疫治疗的临床疗效.方法 2005年1月～2010年5月共40例淋巴瘤患者(治疗组)化疗缓解后进行大剂量 IL-2 免疫治疗,随机挑选的40例患者(对照组),化疗结束缓解后不进行任何免疫治疗,检测两组患者外周血T淋巴细胞亚群,并对所有患者进行随访观察.结果 治疗组外周血T淋巴细胞亚群水平明显提升,随访结束时统计复发率:治疗组17.5%,对照组32.5%;中位生存期:治疗组(34.5±2.0)(20～60)个月,对照组(23.2±2.0)(12～60)个月.结论 恶性淋巴瘤化疗缓解后行大剂量 IL-2治疗是有效的免疫治疗手段,能提高患者的免疫功能,减少复发率,延长生存期,具有潜在临床应用前景.
展开▼
